Find information about GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for health care professionals. Please see Important Safety Information on this website.

Dec 11, 2014 · GARDASIL 9 includes the greatest number of HPV types in any available HPV vaccine . Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine,

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

Jun 12, 2020 · GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers

RAHWAY, N.J., Jan. 28, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today reaffirmed its commitment to defending the safety and efficacy of its HPV vaccines. Merck is a defendant in product liability lawsuits in the United States involving GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and […]

Mar 15, 2024 · Tradename: GARDASIL 9 Manufacturer: Merck Sharp & Dohme LLC Indications: Indicated in girls and women 9 through 45 years of age for the prevention of the following diseases:

GARDASIL® is a vaccine indicated in girls and women 9 through26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:

Tradename: Gardasil Manufacturer: Merck & Co., Inc. Indications: Prevention of vulvar and vaginal cancer

3 days ago · The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

GARDASIL®9, Human Papillomavirus 9 -valent Vaccine, Recombinant, is a vaccine indicated in individuals 9 through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV)